Analysis of the frequency of NRAS and c-Kit gene mutations in patients with BRAF-negative melanoma


Cite item

Full Text

Abstract

Identification of molecular subtypes of melanoma allowed to use a personalized approach in the treatment of melanoma. One of the most common driver mutations in melanoma is a mutation of the oncogene BRAF, that is determined in 40-60% of all melanomas. However, BRAF-negative tumors require further investigation of mutational status, which can be applied not only to select the means of personalized therapy of tumor, but also for the prediction of disease course. This article presents an analysis of 37 patients with melanoma BRAF-negative for mutations in the genes NRAS and c-Kit. Mutations were identified in the 3 exon of the gene NRAS in 8.1% of cases. In skin melanomas «silent» mutations were identified in 64.7% that confirm the occurrence ofpronounced mutation under the influence of ultraviolet radiation on the skin of the patient. We identified clinical and morphological features ofpatients with NRAS mutation in the 3 exon. This group ofpatients is characterized by a greater thickness of the tumor Breslow. Female gender and older age were dominated clinical characteristics in this group as compared with patients without NRAS mutations (p < 0.05).

About the authors

Maria B. Aksenenko

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Email: aksenenko_mariya@mail.ru
MD, PhD, docente, Department of Pathophysiology with a Course of a Clinical Pathophysiology Krasnoyarsk, 660022, Russian Federation

A. V Komina

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Department of Pathophysiology with a course of clinical pathophysiology Krasnoyarsk, 660022, Russian Federation

T. G Ruksha

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Department of Pathophysiology with a course of clinical pathophysiology Krasnoyarsk, 660022, Russian Federation

References

  1. Wick M.R. Cutaneous melanoma: A current overview. Semin. Diagn. Pathol. 2016; 33(4): 225-41. doi: 10.1053/j.semdp.2016.04.007.
  2. Berger M.F., Hodis E., Heffernan T.P., Deribe Y.L., Lawrence M.S., Protopopov A., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012; 485(7399): 502-6.
  3. Muzny D.M., Bainbridge M.N., Chang K., Dinh H.H., Drummond J.A., Fowler G., et al. Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network. Nature. 2012; 487(7407): 330-7. doi: 10.1038/nature11252.
  4. Hodis E.L., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2): 251-63. doi: 10.1016/j.cell.2012.06.024.
  5. Berger M.F., Garraway L.A. Applications of genomics in melanoma oncogene discovery. Hematol. Oncol. Clin. North. Am. 2009; 23(3): 397-414. vii. doi: 10.1016/j.hoc.2009.03.005.
  6. Ponti G., Pellacani G., Tomasi A., Loschi P., Luppi G., Gelsomino F., et al. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-Kit, and GNAQ melanomas. Dis. Markers. 2014; 2014: 671283. doi: 10.1155/2014/671283.
  7. Burd C.E., Liu W., Huynh M.V., Waqas M.A., Gillahan J.E., Clark K.S., et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014; 4(12): 1418-29. doi: 10.1158/2159-8290.CD-14-0729.
  8. Torres-Cabala C.A., Wang W.L., Trent J., Yang D., Chen S., Galbincea J., et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acrallentiginous/mucosal type. Mod. Pathol. 2009; 22(11): 1446-56. doi: 10.1038/modpathol.2009.116.
  9. Tang Y.L., Fan Y.L., Jiang J., Li K.D., Zheng M., Chen W., et al. c-Kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget. 2014; 5(6): 1491-501.
  10. Pozzobon F.C., Puig-Butille J.A., Gonzalez-Alvarez T., Carrera C., Aguilera P., Alos L., et al. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma. Br. J. Dermatol. 2014; 171(4): 754-9. doi: 10.1111/bjd.13069.
  11. Мазуренко Н.Н. Генетическая гетерогенность меланомы кожи: новые мишени для селективного воздействия. Злокачественные опухоли. 2015; 4(2): 3-8. doi: 10.18027/2224-5057-2015-4s2-3-8.
  12. Meszaros B., Zeke A., Remenyi A., Simon I., Dosztanyi Z. Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development. Biol. Direct. 2016; 11: 23. doi: 10.1186/s13062-016-0125-6.
  13. Jiang W., Jia P., Hutchinson K.E., Johnson D.B., Sosman J.A., Zhao Z. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget. 2015; 6(4): 2496-508.
  14. Hutchinson K.E., Lipson D., Stephens P.J., Otto G., Lehmann B.D., Lyle P.L., et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 2013; 19(24): 6696-702.
  15. Fedorenko I.V., Gibney G.T., Smalley K.S. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32(25): 3009-18. doi: 10.1038/onc.2012.453.
  16. Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases. 2011; 2(5): 289-92.
  17. Johnpulle R.A., Johnson D.B., Sosman J.A. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr. Oncol. Rep. 2016; 18(1): 6. doi: 10.1007/s11912-015-0485-6.
  18. Desar I.M., van Herpen C.M., van Erp N.P., Kaal S.E., van de Kerkhof P.C., van der Graaf W.T. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. Anticancer Drugs. 2016; 27(6): 576-9. doi: 10.1097/CAD.
  19. Аксененко М.Б., Рукша М.Б. Инвазивная способность и пролиферативная активность меланомы кожи в зависимости от эпигенетического фактора. Российский журнал кожных и венерических болезней. 2014; 17(5): 4-8.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies